| ID | 1147 |
| Name of the vaccine | Hiberix |
| Microbe | Bacteria |
| Disease name | Haemophilus influenzae type b (Hib) |
| Name of bacteria | Haemophilus influenzae |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 6 weeks to 4 years |
| Description of the vaccine | Haemophilus b Conjugate Vaccine (Tetanus Toxoid Conjugate) (PRP-T). |
| Name of the manufacturer | GlaxoSmithKline Biologicals |
| Name of the manufacturing country | Belgium |
| Year of manufacture | 2009 |
| Clinical Phase status | Approved |
| Bacterial strain | Anaerobic gram-negative coccobacillus. |
| Efficacy | Conducted with unconjugated Haemophilus b polysaccharide vaccine. |
| Vaccine formulation | Lyophilized vaccine to be reconstituted with saline diluent. |
| Dosage | Four dose series (0.5 ml each). Primary series: One dose at 2, 4, and 6 months of age.
Booster: One dose at 15 through 18 months. |
| Mechanism of action | Anti-PRP concentration of 0.15 mcg/mL : minimal protection
Anti-PRP concentration of greater than or equal to 1.0 mcg/mL : Protection for 1 year |
| Route of administration | Intramuscular |
| Indications | Prevention of invasive disease caused by Haemophilus influenzae type b. |
| Export | Distributed by - GlaxoSmithKline, USA |
| Approval | Germany Approval (1996), US FDA (2009) |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Pain and redness, irritability, drowsiness, fever, loss of appetite, fussiness, and restlessness. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/77017/download |
| Other name | NA |
| Additional Links | NA
|